IL2 and chronic inflammatory demyelinating polyradiculoneuropathy: Tacrolimus is a calcineurin inhibitor that interferes with T cell function (via disrupted IL‐2 signalling) [4], so it is mechanistically possible that it could interact with known disease mechanisms in CIDP [26, 27, 28].